BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37403120)

  • 1. Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas.
    Chang YS; Tu SJ; Chen HD; Chung CC; Hsu MH; Chou YP; Lee YT; Yen JC; Jeng LB; Chang JG
    Biomark Res; 2023 Jul; 11(1):68. PubMed ID: 37403120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genomic analyses of hepatocellular carcinoma.
    Chang YS; Tu SJ; Chen HD; Hsu MH; Chen YC; Chao DS; Chung CC; Chou YP; Chang CM; Lee YT; Yen JC; Jeng LB; Chang JG
    Hepatol Int; 2023 Feb; 17(1):97-111. PubMed ID: 36472800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.
    Lee M; Kim K; Kim SY; Jung SH; Yoon J; Kim MS; Park HC; Jung ES; Chung YJ; Lee SH
    Hum Pathol; 2018 Nov; 81():37-46. PubMed ID: 29949741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
    Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
    World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.
    Wang S; Shi H; Liu T; Li M; Zhou S; Qiu X; Wang Z; Hu W; Guo W; Chen X; Guo H; Shi X; Shi J; Zang Y; Cao J; Wu L
    Hepatobiliary Surg Nutr; 2021 Apr; 10(2):172-179. PubMed ID: 33898558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
    Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
    J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
    Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.
    Miao R; Luo H; Zhou H; Li G; Bu D; Yang X; Zhao X; Zhang H; Liu S; Zhong Y; Zou Z; Zhao Y; Yu K; He L; Sang X; Zhong S; Huang J; Wu Y; Miksad RA; Robson SC; Jiang C; Zhao Y; Zhao H
    J Hepatol; 2014 Oct; 61(4):840-9. PubMed ID: 24859455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma.
    Li L; Rao X; Wen Z; Ding X; Wang X; Xu W; Meng C; Yi Y; Guan Y; Chen Y; Wang J; Jun L
    Oncol Lett; 2020 Apr; 19(4):2739-2748. PubMed ID: 32218826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia associated multi-omics molecular landscape of tumor tissue in patients with hepatocellular carcinoma.
    Zhang Q; Qiao L; Liu Q; Kong X; Hu J; Hu W; Wu Z; Li M; Liu L
    Aging (Albany NY); 2021 Mar; 13(5):6525-6553. PubMed ID: 33690171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
    J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
    Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
    J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
    Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
    Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers.
    Shiraishi Y; Fujimoto A; Furuta M; Tanaka H; Chiba K; Boroevich KA; Abe T; Kawakami Y; Ueno M; Gotoh K; Ariizumi S; Shibuya T; Nakano K; Sasaki A; Maejima K; Kitada R; Hayami S; Shigekawa Y; Marubashi S; Yamada T; Kubo M; Ishikawa O; Aikata H; Arihiro K; Ohdan H; Yamamoto M; Yamaue H; Chayama K; Tsunoda T; Miyano S; Nakagawa H
    PLoS One; 2014; 9(12):e114263. PubMed ID: 25526364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a Comprehensive Multiomics Map of Hepatocellular Carcinoma and Screening of Possible Driver Genes.
    Liu Z; Lin Y; Gao X; Mai R; Piao X; Ye J; Liang R
    Front Genet; 2020; 11():634. PubMed ID: 32670354
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
    Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
    BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.